ANDA 90557, held by Jubilant Cadista. Alendronate Sodium.
As of Nov 16, 2026, ANDA 90557 (Alendronate Sodium), held by Jubilant Cadista, was first approved by FDA on Feb 18, 2010, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 18, 2010 | Original application | Approved | None posted |
| Alendronate SodiumEQ 5MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Oct 14, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 21, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 21, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 10, 2012 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 30, 2012 | Supplement 1Labeling | Approved | None posted |
| Feb 18, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters